T1	Participants 34 45	multicenter
T2	Participants 542 651	Patients that had nonexudative age-related macular degeneration (AMD) and certain hemorheologic abnormalities
T3	Participants 872 895	A total of 216 patients
T4	Participants 913 1124	Of these, 18 were not included in the vision or adverse events evaluation because they did not complete one treatment. This decreased the number of patients that were evaluated for adverse events to 198 patients
